激活RARβ克服t(4;14)多发性骨髓瘤对免疫调节药物的耐药
该研究对1855种FDA批准药物进行高通量筛选,发现全反式维甲酸(ATRA)本身无抗骨髓瘤作用,但可增强免疫调节药物(IMiDs)对t(4;14)骨髓瘤细胞的杀伤。机制上ATRA激活RARβ,与HDAC5/HDAC3形成共抑制复合物,降低FGFR3启动子染色质可及性及H3K27乙酰化,抑制FGFR3表达及PI3K/AKT通路;选择性RARβ激动剂CD2314在体内外使t(4;14)细胞对IMiDs敏感或再敏感。
要点
- ATRA单药无抗骨髓瘤作用,但增强IMiDs对t(4;14)骨髓瘤细胞的毒性。
- RARβ激动剂CD2314在体内外使t(4;14)细胞对IMiDs敏感并逆转耐药。
- 机制涉及RARβ-HDAC5/HDAC3共抑制复合物降低FGFR3启动子可及性。
核心结论
- ATRA和RARβ激动剂可增强IMiDs对t(4;14)多发性骨髓瘤的疗效,为克服IMiD耐药提供策略。
研究设计与样本
- 对1855种FDA批准药物进行高通量筛选,并在t(4;14)骨髓瘤细胞及体内外模型中验证。
主要发现
- ATRA本身无抗骨髓瘤效果,但增强IMiDs对t(4;14)骨髓瘤细胞的细胞毒性。
- ATRA激活RARβ,RARβ与HDAC5、HDAC3形成共抑制复合物,降低FGFR3启动子染色质可及性和H3K27乙酰化,抑制FGFR3表达及PI3K/AKT信号。
- IMiDs通过降低HDAC5 Ser498磷酸化水平增强HDAC5和HDAC3核转位。
- 选择性RARβ激动剂CD2314在体外和体内使t(4;14)骨髓瘤细胞对IMiDs敏感并再敏感。
临床怎么用
- 对t(4;14)多发性骨髓瘤患者,可考虑联合ATRA或RARβ激动剂以增强IMiDs疗效并克服耐药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The t(4;14) translocation is a high-risk cytogenetic abnormality in multiple myeloma (MM) that results in overexpression of fibroblast growth factor receptor 3 (FGFR3) and enhanced MM proliferation, leading to poor prognosis. Herein, we carried out a high-throughput screen on 1855 Food and Drug Administration (FDA)-approved pharmaceuticals and identified all-trans retinoic acid (ATRA), which alone has no anti-MM effect, as a potent drug that enhances the cytotoxic effects of immunomodulatory drugs (IMiDs) in t(4;14) MM cells. Mechanistically, ATRA activates retinoic acid receptor β (RARβ), which then binds to retinoic acid response elements in the FGFR3 promoter. IMiDs enhanced nuclear translocation of histone deacetylase (HDAC)-5 and 3 by reducing HDAC5 Ser498 phosphorylation levels. RARβ, HDAC5 and HDAC3 formed a co-repressor complex that reduced chromatin accessibility and H3K27 acetylation in FGFR3 promoter, FGFR3 expression, and suppressed phosphoinositide 3-kinase/AKT signaling pathways, leading to more MM cell death. Similarly, CD2314, a selective RARβ agonist, sensitized and resensitized t(4;14) MM cells to IMiDs in vitro and in vivo. Thus, these findings underscore the therapeutic potential of ATRA and RARβ agonists in enhancing the efficacy of IMiD-based treatments for t(4;14) MM and offer a promising strategy to overcome IMiD resistance and improve outcomes in this high-risk subgroup.
引用
- Zhong L, Wang Q, Xian M, et al. Activating RARβ to overcome immunomodulatory drug resistance in t(4;14) human myeloma. Leukemia. 2026. PMID: 42533031. doi:10.1038/s41375-026-03078-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。